Lawriter - OAC - 4729:8-3-02 Information required for submission.

4729:8-3-02 Information required for submission.

(A) Pharmacies pursuant to paragraphs (A) and (B) of rule 4729:8-3-01 of the Administrative Code that dispense drugs listed in Chapter 4729:8-2 of the Administrative Code to outpatients shall report the following dispensing information to the board of pharmacy in accordance with rule 4729:8-3-03 of the Administrative Code:

(1) Pharmacy drug enforcement administration registration number. If not applicable, another mutually acceptable identifier;

(2) Pharmacy name;

(3) Pharmacy address;

(4) Pharmacy telephone number;

(5) Patient full name;

(6) Patient residential address;

(7) Patient telephone number;

(8) Patient date of birth;

(9) Patient gender;

(10) Prescriber's full name (first name and last name);

(11) Prescriber's drug enforcement administration registration number. If not applicable, another mutually acceptable identifier;

(12) Date prescription was issued by the prescriber;

(13) Date the prescription was dispensed or sold by the pharmacy;

(14) Indication of whether the prescription dispensed is new or a refill;

(15) Number of the refill being dispensed;

(16) National drug code of the drug dispensed;

(17) Quantity of the drug prescribed;

(18) Quantity of drug dispensed;

(19) Number of days' supply of the drug dispensed as indicated by the prescriber pursuant to agency 4729 of the Administrative Code, except as follows:

(a) If a days' supply is not indicated by the prescriber, the pharmacy shall calculate and report the number of days' supply of the drug dispensed;

(b) If the quantity of drug dispensed is different from the quantity indicated on the prescription, the pharmacy shall calculate and report the number of days' supply of the drug dispensed.

(20) Serial or prescription number assigned to the prescription order;

(21) Source of payment for the prescription that indicates one of the following: private pay (cash), medicaid, medicare, commercial insurance, or workers' compensation;

(22) Pharmacy national provider identification (NPI) number;

(23) Prescriber's national provider identification (NPI) number, if prescriber does not have an NPI, then another mutually acceptable identifier;

(24) Any of the following as indicated by the prescriber pursuant to agency 4729 of the Administrative Code:

(a) The ICD-10-CM medical diagnosis code of the primary disease or condition that the controlled substance drug is being used to treat. The code shall, at a minimum, include the first four alpha-numeric characters of the ICD-10-CM medical diagnosis code, sometimes referred to as the category and the etiology (ex. M 16.5 );

(b) For dentists licensed pursuant to Chapter 4715. of the Revised Code, the "Code on Dental Procedures and Nomenclature" (CDT code), as published by the American dental association, of the dental treatment requiring the controlled substance prescription;

(c) If no such code is indicated on the prescription, the pharmacy shall indicate "NC" in the diagnosis data field.

(B) Prescribers pursuant to paragraph (E) of rule 4729:8-3-01 of the Administrative Code that personally furnish drugs listed in Chapter 4729:8-2 of the Administrative Code shall report the following information to the board of pharmacy in accordance with rule 4729:8-3-03 of the Administrative Code:

(1) Prescriber drug enforcement administration registration number. If not applicable, another mutually acceptable identifier;

(2) Prescriber full name (first and last name);

(3) Prescriber address;

(4) Prescriber telephone number;

(5) Patient full name;

(6) Patient residential address;

(7) Patient telephone number;

(8) Patient date of birth;

(9) Patient gender;

(10) Date the drug was personally furnished by the prescriber;

(11) National drug code of the drug personally furnished;

(12) Quantity of drug personally furnished;

(13) Number of intended days' supply of drug personally furnished;

(14) Source of payment for the prescription that indicates one of the following: private pay (cash), medicaid, medicare, commercial insurance, or workers' compensation;

(15) Either of the following:

(a) The ICD-10-CM medical diagnosis code of the primary disease or condition that the controlled substance drug is being used to treat. The code shall, at a minimum, include the first four alpha numeric characters of the ICD-10-CM medical diagnosis code, sometimes referred to as the category and the etiology (ex. M 16.5 );

(b) For dentists licensed pursuant to Chapter 4715. of the Revised Code, the "Code on Dental Procedures and Nomenclature" (CDT code), as published by the American dental association, of the dental treatment requiring the controlled substance prescription.

(C) Drug distributors and terminal distributors pursuant to paragraphs (C) and (D) of rule 4729:8-3-01 of the Administrative Code that sell at wholesale drugs listed in Chapter 4729:8-2 of the Administrative Code shall report the following information to the board of pharmacy in accordance with rule 4729:8-3-03 of the Administrative Code:

(1) Drug distributor or terminal distributor drug enforcement administration registration number. If not applicable, then another mutually acceptable identifier;

(2) Purchaser's drug enforcement administration registration number. If not applicable, then another mutually acceptable identifier;

(3) National drug code number of the drug sold;

(4) Quantity of the drug sold;

(5) Date of sale; and

(6) Transaction identifier or invoice number.

(D) Drug distributors shall report suspicious orders and customer information pursuant to rule 4729:6-3-05 of the Administrative Code to the drug database established in section 4729.75 of the Revised Code.

Replaces: 4729-37-04


Effective: 3/15/2019
Five Year Review (FYR) Dates: 03/15/2024
Promulgated Under: 119.03
Statutory Authority: 3719.28, 4729.26, 4729.84
Rule Amplifies: 4729.75, 4729.76, 4729.77, 4729.78, 4729.79, 4729.80, 4729.81, 4729.82, 4729.83, 4729.84
Prior Effective Dates: 01/01/2006, 04/27/2007, 10/19/2007, 01/01/2011, 10/27/2011, 05/22/2014, 01/15/2016, 12/01/2016